Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE AND OLMESARTAN MEDOXOMIL versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE AND OLMESARTAN MEDOXOMIL versus TEVETEN HCT.
AMLODIPINE AND OLMESARTAN MEDOXOMIL vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, resulting in vasodilation and decreased aldosterone secretion.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Initial: 5 mg/20 mg orally once daily. Titrate after 1-2 weeks. Maximum: 10 mg/40 mg daily.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Amlodipine: 30-50 hours (steady-state achieved after 7-8 days; permits once-daily dosing). Olmesartan: 10-15 hours.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Amlodipine: ~60% renal (10% unchanged, 50% as metabolites), ~20-25% biliary/fecal. Olmesartan: ~35-50% renal (unchanged), ~50-65% biliary/fecal (unchanged).
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination